# Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation

> **NCT04293809** · PHASE1 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 30 (actual)

## Conditions studied

- Breast Augmentation

## Interventions

- **DRUG:** Exparel Injectable Product
- **DRUG:** Bupivacaine Hydrochloride

## Key facts

- **NCT ID:** NCT04293809
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2020-01-15
- **Final completion:** 2020-01-29
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04293809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04293809, "Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04293809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*